Visión generalGráficoNoticiasTraderScreen

L&S Knock-Out Axsome Therapeutics.../  DE000LX32WU9  /

Lang & Schwarz
12/11/2024  23:00:23 Diferencia+0.77 Bid23:00:23 Ask23:00:23 Subyacente Precio de ejercicio Fecha de expiración Tipo de opción
3.44EUR +28.84% 3.44
Volumen de oferta: -		 3.74
Tamaño/ Volumen/ Formato de Ask: -		 - 60.7069 EUR 31/12/2078 Call
GlobeNewswire 27/08 Axsome Therapeutics to Participate in Investor Conferences in September
GlobeNewswire 21/08 Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sando...
GlobeNewswire 05/08 Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 11/07 Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
GlobeNewswire 05/06 Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
GlobeNewswire 04/06 Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During...
GlobeNewswire 03/06 Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
GlobeNewswire 30/05 Axsome Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire 29/05 Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function ...
GlobeNewswire 28/05 Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Ps...
GlobeNewswire 08/05 Axsome Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire 06/05 Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 01/05 Axsome Therapeutics Recognizes May as Mental Health Awareness Month
GlobeNewswire 15/04 Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurolog...
GlobeNewswire 10/04 Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
GlobeNewswire 01/04 Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating...
GlobeNewswire 25/03 Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Nee...
GlobeNewswire 25/03 Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narc...
GlobeNewswire 19/03 Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depr...
GlobeNewswire 05/03 Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
GlobeNewswire 20/02 Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Busines...
GlobeNewswire 23/01 Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
GlobeNewswire 04/01 Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anti...
GlobeNewswire 11/12/2023 Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depr...
GlobeNewswire 07/12/2023 Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today